| Project/Area Number |
03670648
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Fukuoka University |
|---|
Principal Investigator |
KUMASHIRO Ryunosuke Fukuoka Univ.Med.Associate Prof., 医学部・第2外科, 助教授 (50094769)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OKADA Hidechika Nagoya City Univ.Med.Prof., 医学部, 教授 (30160683)
HIDESHIMA Teru , 講師 (00238312)
犬塚 貞光 福岡大学, 医学部・第2外科, 教授 (00090746)
|
|---|
| Project Period (FY) |
1991 – 1993
|
| Project Status |
Completed (Fiscal Year 1993)
|
| Budget Amount *help |
¥2,100,000 (Direct Cost: ¥2,100,000)
Fiscal Year 1993: ¥300,000 (Direct Cost: ¥300,000)
Fiscal Year 1992: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1991: ¥1,200,000 (Direct Cost: ¥1,200,000)
|
|---|
| Keywords | Bispecific antibody / CD3 / CEA / Cytotoxicity |
|---|
| Research Abstract |
1. A mouse anti-human CEA x anti-human CD3 bispecific antibody was developed.
2. This antibody-heteroconjugate was prepared by chemical cross-inking the AB5C10 monoclonal antibody reactive with human CEA with the monoclonal antibody UCHT1, which binds to CD3 on human T-lymphocytes. The bispecific antibody recognized CEA expressed on the KATO lll cell line and CD3 expressed on the T-lymphocyte using the flowcytometry.
3. The bispecific antibody-mediated cytolysis was demonstrated by ^<51>Cr-release assay. When target ^<51>Cr-labeled KATO lll cells were incubated for 6hr with effector cells which were pretreated with bispecific antibody for 30 min.at 4ﾟC, % specific lysis was significantly increased compaired to the non-treated effector cells. Using peripheral blood mononuclear cells (PBMC) and lymphokine-activated killer cells for effector cells, % specific lysis was 15.3% and 57.4% at the E/T ratio was 100/1 and 12/1, respectively.
4. The effective dose of bispecific antibody required antibody-mediated cytotoxicity was 0.1 mug/ml.
5. The results suggested the usefulness of anti-CEA x anti-CD3 bispecific antibody for augumentation of cytotoxicity of CD3 positive T-cells against CEA positive cells in vitro.
|
